Ova-Mit (Clomifene Citrate)

Clomifene citrate, the active ingredient in Ova-Mit, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It is employed to stimulate ovulation in women with anovulatory infertility, including polycystic ovary syndrome, and is indicated for use under medical supervision to improve chances of conception.

GNH USA supplies Ova-Mit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance across global markets.

Clomifene citrate is a selective estrogen receptor modulator used in reproductive medicine to stimulate ovulation.

- Anovulation due to polycystic ovary syndrome: induces ovulation and improves the likelihood of conception. - Infertility associated with anovulatory disorders: facilitates follicular development and increases pregnancy rates. - Clomiphene‑resistant ovulation induction (adjunct): may enhance ovarian response when combined with other fertility agents.

Clomifene citrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Hot flashes: transient warmth and sweating. - Mood swings: emotional variability. - Nausea: mild gastrointestinal upset. - Breast tenderness: discomfort in breast tissue. - Headache: mild to moderate intensity. - Visual disturbances: blurred vision or spots.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: excessive ovarian response with abdominal pain and fluid shift. - Multiple pregnancy: increased chance of twins or higher order gestations. - Ovarian cyst formation: cystic lesions that may require monitoring. - Thromboembolic events: rare clot formation. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should assess individual risk factors and monitor patients for adverse events.

- Baseline ovarian assessment: evaluate follicular status via ultrasound. - Visual monitoring: advise patients to report any visual changes promptly. - Hepatic function: check liver enzymes in patients with known liver disease. - Pregnancy avoidance: ensure effective contraception until ovulation is confirmed. - Multiple pregnancy counseling: discuss the increased risk of twins or higher order gestations. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Clomifene citrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Concomitant hormonal contraceptives: may reduce clomifene effectiveness. - Warfarin: clomifene may potentiate anticoagulant activity, increasing bleeding risk. - Strong CYP2D6 inhibitors: can affect clomifene metabolism and plasma levels.

Moderate Interactions (Monitor Closely): - Gonadotropins: combined use raises the risk of ovarian hyperstimulation. - Thyroid hormone therapy: may require dose adjustments based on thyroid status. - Selective serotonin reuptake inhibitors: can exacerbate mood‑related side effects.